FDA Plays

[ToysInTheAttic]

ALIM on radar - Three PT's $15-16

CS,Oppenheimer,Citi out w/ pt's $15-16

Business Summary
http://www.alimerasciences.com/

Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien, which the Company is developing for the treatment of diabetic macular edema (DME). The Company has completed enrollment of 956 patients in two Phase 3 pivotal clinical trials for the use of Iluvien in the treatment of DME across the United States, Canada, Europe and India. Iluvien is an intravitreal insert designed to provide a sustained therapeutic effect for up to 36 months by delivering a low daily dose of fluocinolone acetonide (FA), a corticosteroid with demonstrated efficacy in the treatment of ocular diseases. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound.